Status:
RECRUITING
Efficacy And Safety Of Hydroxychloroquine Combined With Methotrexate, Capecitabine And Bevacizumab Vs. Regorafenib In Participants With Refractory Metastatic Colorectal Cancer With Mutations In RAS Genes
Lead Sponsor:
Sergey Orlov, MD
Conditions:
Metastatic Colorectal Cancer (mCRC)
Colorectal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will evaluate efficacy and safety of hydroxychloroquine combined with methotrexate, capecitabine and bevacizumab versus regorafenib in participants with refractory metastatic colorectal can...
Detailed Description
One potential therapeutic option for pretreated patients with RAS-positive metastatic colorectal cancer (mCRC) could be hydroxychloroquine. The KRAS mutation drives uncontrolled proliferation and cell...
Eligibility Criteria
Inclusion
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Provide written informed consent
- Age ≥ 18 years
- Histologically confirmed diagnosis of colorectal cancer (CRC) with distant metastases.
- Presence of mutations in the KRAS or NRAS gene.
- Participants must have previously treated for metastatic colorectal cancer and experienced disease progression during receiving at least 2 lines of systemic chemotherapy in combination with antiangiogenic agents.
- Patient has previously received oxaliplatin- and irinotecan-containing regimens and developed resistance to these chemotherapeutic agents.
Exclusion
- Presence of clinically significant cardiovascular disease: severe or unstable ischemic heart disease, history of myocardial infarction, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias.
- Stroke and/or transient ischemic attack within 6 months prior to screening;
- Uncontrolled hypertension
- History of previous malignancies except non-melanoma skin cancers, or in situ cervical or breast cancer unless a complete remission was achieved at least 2 years prior to randomization AND no additional therapy is required during the study period. Patients having hepatic involvement of cancer should be excluded as per investigator assessment.
- Patients with CNS metastases are eligible only if the metastases are adequately treated.
- Absolute neutrophil count (ANC) \<1.5×109/L, platelet count \<100×109/L, or hemoglobin \<9.0 g/dL.
- Serum total bilirubin \>1.5 × the upper limit of normal (ULN). Participants with Gilbert syndrome, bilirubin \<2 X ULN, and normal AST/ALT are eligible;
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 × ULN;
- Serum creatinine \>1.5 × ULN.
- History of a thromboembolic event
- Presence of any allergic reactions to components of the study drugs
- Concomitant medications with a known risk of causing QT prolongation and/or Torsades de Pointes.
- Any anti-cancer systemic therapy, radiation therapy
- Women who are pregnant or lactating;
- Presence of unresolved adverse events of grade 2 or higher toxicity, according to CTCAE v5.0 criteria, from prior therapy (except for alopecia or neurotoxicity grade≤2).
- Any other serious or uncontrolled medical disorder, active infection, physical examination finding, laboratory finding, altered mental status, or psychiatric condition that, in the opinion of the investigator, would limit a patient's ability to comply with the study requirements, substantially increase risk to the patient, or impact the interpretability of study results.
Key Trial Info
Start Date :
March 17 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06949982
Start Date
March 17 2025
End Date
October 1 2027
Last Update
May 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Pavlov State Medical University
Saint Petersburg, Sankt-Peterburg, Russia, 197022